Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer (ALEXANDRIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02654639
Recruitment Status : Terminated (Principal investigator left the institution)
First Posted : January 13, 2016
Results First Posted : August 7, 2018
Last Update Posted : August 7, 2018
Information provided by (Responsible Party):
Georgetown University

Brief Summary:
Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: TAS-102 Drug: Bevacizumab Phase 2

Detailed Description:

Study Drug:

TAS-102 (trifluridine and tipiracil hydrocholoride) and bevacizumab

Dosing Details:

Starting dose of TAS-102 is 35 mg/m2 administered orally twice daily, after meals, for 5 days a week with 2 days rest for 14 days, followed by 14 days rest (1 treatment cycle).

Bevacizumab 5 mg/kg intravenously every 14 days. The treatment cycle repeats every 28 days. Patients may take TAS-102 plus bevacizumab until they exhibit progression of disease, withdraw consent, or experience unacceptable toxicity.This is a single arm study. All patients receive the same study treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-center, Phase 2 Study of Switch Maintenance With TAS-102 Plus Bevacizumab Following Oxaliplatin or Irinotecan-Based Fluoropyrimidine-Containing Induction Chemotherapy in Patients With Metastatic Colorectal Cancer
Actual Study Start Date : February 2016
Actual Primary Completion Date : November 2017
Actual Study Completion Date : November 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: TAS-102 and Bevacizumab
Oral TAS-102 and intravenous Bevacizumab.
Drug: TAS-102
TAS-102 Twice a day by mouth day 1-5 and 8-12
Other Names:
  • Lonsurf
  • Avastin

Drug: Bevacizumab
Bevacizumab by intravenous infusion once every 14 days

Primary Outcome Measures :
  1. Length of Progression-Free Survival [ Time Frame: From the first occurrence of progression or death, whichever occurred first, assessed up to 2 years. ]
    Disease progression will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Written informed consent
  • Histologically proven, unresectable, evaluable metastatic colorectal cancer
  • 16 to 20 weeks of first-line therapy with oxaliplatin, and/or irinotecan-based flourorpyrimidine-containing chemotherapy plus Bevacizumab
  • Patients must have stable disease (or better) during the initial induction chemotherapy with first-line chemotherapy.
  • No progressive disease at the time of initiation of maintenance therapy
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
  • Adequate organ and marrow function
  • Women of child-bearing potential and men must agree to avoid pregnancy
  • Patient must start maintenance therapy at least 14 days after the last administered induction chemotherapy but no later than 30 days.

Exclusion Criteria

  • Patients whose tumors have progressed on first-line treatment
  • Patients with active concurrent malignancy, other than superficial, non-invasive squamous cell carcinoma of the skin or uterine cervix, within the past three years.
  • Women who are pregnant or lactating
  • Unstable heart disease
  • Uncontrolled active infection requiring antibiotics within one week prior to first dose.
  • Patients with active CNS malignancy.
  • Persistent protein in the urine
  • Patients with bowel obstruction or uncontrolled vomiting.
  • Patients with serious psychiatric or medical conditions that could interfere with treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02654639

Layout table for location information
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
Layout table for investigator information
Principal Investigator: Mohamed Salem, MD Georgetown University
  Study Documents (Full-Text)

Documents provided by Georgetown University:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Georgetown University Identifier: NCT02654639    
Other Study ID Numbers: 2015-0959
First Posted: January 13, 2016    Key Record Dates
Results First Posted: August 7, 2018
Last Update Posted: August 7, 2018
Last Verified: April 2018
Keywords provided by Georgetown University:
Metastatic Colorectal Cancer
Advanced Colorectal Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors